COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

166.62

Increased from previous period

OCF/share of 166.62 while Medical - Pharmaceuticals median is zero. Walter Schloss would see if modest cash generation can build a stronger lead.

Free Cash Flow per Share

143.69

Increased from previous period

Positive FCF/share while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong edge over peers.

Capex-to-Operating Cash Flow

13.76%

Increased from previous period

Capex/OCF ratio of 13.76% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.

Income Quality Ratio (OCF / Net Income)

3.04

Increased from previous period

Ratio above 1.5x Medical - Pharmaceuticals median of 0.97. Joel Greenblatt would see if robust OCF is a recurring trait.

Operating Cash Flow-to-Sales Ratio

13.59%

Increased from previous period

OCF-to-sales ratio of 13.59% while Medical - Pharmaceuticals is zero. Walter Schloss might see a modest advantage in actually generating some cash.

Select Chart Metric:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

166.62

Increased from previous period

OCF/share of 166.62 while Medical - Pharmaceuticals median is zero. Walter Schloss would see if modest cash generation can build a stronger lead.

Free Cash Flow per Share

143.69

Increased from previous period

Positive FCF/share while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong edge over peers.

Capex-to-Operating Cash Flow

13.76%

Increased from previous period

Capex/OCF ratio of 13.76% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.

Income Quality Ratio (OCF / Net Income)

3.04

Increased from previous period

Ratio above 1.5x Medical - Pharmaceuticals median of 0.97. Joel Greenblatt would see if robust OCF is a recurring trait.

Operating Cash Flow-to-Sales Ratio

13.59%

Increased from previous period

OCF-to-sales ratio of 13.59% while Medical - Pharmaceuticals is zero. Walter Schloss might see a modest advantage in actually generating some cash.

Select Chart Metric: